公开(公告)号：US20230219962A1

公开(公告)日：2023-07-13

申请号：US17927222

申请日：2021-06-03

申请人： Jianming BAO ,  Natalija CERNAKA ,  Scott D. HOLLINGSWORTH ,  Madeleine Eileen KIEFFER ,  Simon B. LANG ,  Akash M. PATEL ,  W. Michael SEGANISH ,  Merck Sharp & Dohme LLC

发明人： Jianming Bao ,  Natalija Cernaka ,  Scott A. Hollingsworth ,  Madeleine Eileen Kieffer ,  Simon B. Lang ,  Akash M. Patel ,  W. Michael Seganish

IPC分类号： C07D487/04 ,  C07D519/00 ,  A61K39/395 ,  A61K31/519

CPC分类号： C07D487/04 ,  C07D519/00 ,  A61K39/3955 ,  A61K31/519

摘要： The present invention relates to novel Pyrazolo[4,3 -d]Pyrimidine Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one Pyrazolo[4,3-d]Pyrimidine Derivative, and methods of using the Pyrazolo[4,3-d]Pyrimidine Derivatives for treating or preventing a cellular proliferative disorder in a patient.

公开(公告)号：US20230416227A1

公开(公告)日：2023-12-28

申请号：US18043357

申请日：2021-09-09

申请人： Merck Sharp & Dohme LLC ,  Anthony Ken OGAWA ,  Christopher J. SINZ ,  Jacqueline D. HICKS ,  Alan C. CHENG ,  Song YANG ,  Jianming BAO ,  Donna A. A. W. HAYES ,  Simon B. LANG ,  Maoqun TIAN ,  Salman JABRI ,  Galen Paul SHEARN-NANCE ,  Rongze KUANG ,  Zhiqiang ZHAO ,  Zhicai WU

发明人： Anthony Ken Ogawa ,  Christopher J. Sinz ,  Jacqueline D. Hicks ,  Alan C. Cheng ,  Song Yang ,  Jianming Bao ,  Donna A. A. W. Hayes ,  Simon B. Lang ,  Maoqun Tian ,  Salman Jabri ,  Galen Paul Shearn-Nance ,  Rongze Kuang ,  Zhiqiang Zhao ,  Zhicai Wu

IPC分类号： C07D401/14 ,  A61K45/06 ,  A61P9/10

CPC分类号： C07D401/14 ,  A61P9/10 ,  A61K45/06

摘要： The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.